Osteitis fibrosa cystica; Hyperparathyroidism - osteitis fibrosa; Brown tumor of bone
Osteitis fibrosa is a complication of hyperparathyroidism, a condition in which certain bones become abnormally weak and deformed.
The parathyroid glands are 4 tiny glands in the neck. These glands produce parathyroid hormone (PTH). PTH helps control calcium, phosphorus, and vitamin D levels in the blood and is important for healthy bones.
Too much parathyroid hormone (hyperparathyroidism) can lead to increased bone breakdown, which can cause bones to become weaker and more fragile. Many people with hyperparathyroidism eventually develop osteoporosis. Not all bones respond to PTH in the same way. Some develop abnormal areas where the bone is very soft and has almost no calcium in it. This is osteitis fibrosa.
In rare cases, parathyroid cancer causes osteitis fibrosa.
Osteitis fibrosa is now very rare in people who have hyperparathyroidism who have good access to medical care. It is more common in people who develop hyperparathyroidism at a young age, or who have untreated hyperparathyroidism for a long time.
Osteitis fibrosa may cause bone pain or tenderness. There may be fractures (breaks) in the arms, legs, or spine, or other bone problems.
Hyperparathyroidism itself may cause any of the following:
Blood tests show a high level of calcium, parathyroid hormone, and alkaline phosphatase (a bone chemical). Phosphorus level in the blood may be low.
Most of the bone problems from osteitis fibrosa can be reversed with surgery to remove the abnormal parathyroid gland(s). Some people may choose not to have surgery, and instead be followed with blood tests and bone measurements.
If surgery is not possible, medicines can sometimes be used to lower calcium level.
Complications of osteitis fibrosa include any of the following:
Contact your health care provider if you have bone pain, tenderness, or symptoms of hyperparathyroidism.
Routine blood tests done during a medical checkup or for another health problem usually detect a high calcium level before severe damage is done.
Nadol JB, Quesnel AM. Otologic manifestations of systemic disease. In: Flint PW, Francis HW, Haughey BH, et al, eds. Cummings Otolaryngology: Head and Neck Surgery. 7th ed. Philadelphia, PA: Elsevier; 2021:chap 151.
Patsch JM, Krestan CR. Metabolic and endocrine skeletal disease. In: Adam A, Dixon AK, Gillard JH, Schaefer-Prokop CM, eds. Grainger & Allison's Diagnostic Radiology. 7th ed. Philadelphia, PA: Elsevier; 2021:chap 43.
Thakker RV. The parathyroid glands, hypercalcemia and hypocalcemia. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 232.BACK TO TOP
Review Date: 5/13/2020
Reviewed By: Brent Wisse, MD, board certified in Metabolism/Endocrinology, Seattle, WA. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2022 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.